Deep profiling of platelet hyperactive phenotypes in diabetes
- Years funded:
- 2017 - 2019
High blood sugar from diabetes is one of the biggest risk factor linked to the lethal cardiovascular disease. In Australia, 1.7 million people have diabetes with a new person diagnosed every 5 minutes. Diabetic individuals are more prone to develop blood clots causing heart attack and stroke, and these clots are more resistant to standard anticlotting therapies. This project aims to understand how diabetes dysregulates the clotting mechanism and causes resistance to conventional anti-thrombotic drugs. The learnt insights identified biomarkers and developed high-throughput analysis will aid in the development of new diagnostic tools against cardiovascular risk factors, thereby helping predict acute thrombosis and prevent cardiovascular disease.
The success of this study will lead to two cardiovascular health outcomes:
1. Identify new approaches to reduce the prothrombotic effect of diabetes. Our preliminary data have demonstrated that pharmacological inhibition of a specific signalling pathway of an adhesion receptor (integrin) on blood clotting cells (platelet) have therapeutic potential without increasing bleeding risk in preclinical animal models and Phase I human trials.
2. Develop a high-throughput single-cell analysis platform for the discovery and monitoring of cellular biomarkers to track disease, stratify patients and assess the success of therapy, shedding light on future precision medicine in cardiovascular diseases.
Dr Lining Ju
|Institute:||University of Sydney|